The primary objective of the study was to evaluate the long term safety of PRALUENT in
participants with heterozygous familial hypercholesterolemia (heFH) or non-familial
hypercholesterolemia (FH) participants at high or very high cardiovascular risk who completed
the neurocognitive function study R727-CL-1532 (NCT02957682).
The secondary objectives of the study were:
- To evaluate the effect of PRALUENT on low-density lipoprotein cholesterol (LDL-C)
- To evaluate the effect of PRALUENT on other lipid parameters
- To evaluate the effect of PRALUENT on gonadal steroid hormones